Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis
-
Abstract Number: 1139
Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
-
Abstract Number: 1140
Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study
-
Abstract Number: 1141
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
-
Abstract Number: 1142
Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review Using Indirect Comparisons
-
Abstract Number: 1143
Tocilizumab Therapy in Children with Systemic Onset Juvenile Idiopathic Arthritis. Russian Experience
-
Abstract Number: 1144
Phenotypic Characterization of Childhood Onset Rheumatoid Arthritis
-
Abstract Number: 1145
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
-
Abstract Number: 1146
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
-
Abstract Number: 1147
Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS
-
Abstract Number: 1148
Adalimumab – Effective Control under Refractory JIA Associated Uveitis
-
Abstract Number: 1149
Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
-
Abstract Number: 1150
Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project
-
Abstract Number: 1151
Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide
-
Abstract Number: 1152
Improvement in Health-Related Quality of Life for Children with Juvenile Ideopathic Arthritis After Start of Treatment with Etanercept
-
Abstract Number: 1153
Perceived Health-Related Quality of Life and Its Determining Factors in Children with Recent-Onset JIA
-
Abstract Number: 1154
Impact of FokI VDR and TNFalpha–308 Polymorphism On Disease Severity and Long Term Outcome in JIA Patients On Anti-TNF Treatment
-
Abstract Number: 1155
A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis
-
Abstract Number: 1156
Effectivity of Methotrexate in Therapy of Juvenile Idiopathic Enthesitis-Related Arthritis
-
Abstract Number: 1157
The Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children
-
Abstract Number: 1158
Development of Cut-off Values for High Disease Activity in Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis Disease Activity Score
-
Abstract Number: 1159
Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS)
-
Abstract Number: 1160
Assessment of Subclinical Synovitis by Power Doppler Ultrasonography in Patients with Juvenile Idiopathic Arthritis
-
Abstract Number: 1161
Current Evidence of Anti-TNFα Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach Comparing the Different Drugs
-
Abstract Number: 1162
Patients with Juvenile Idiopathic Arthritis From a Low Socio-Economic Background Perceive Their Disease Activity and Physical Limitations Higher Than Patients from a High Socio-Economic Background
-
Abstract Number: 1163
Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
-
Abstract Number: 1164
Orofacial Anomalies in Children with Confirmed Juvenile Idiopathic Arthritis
-
Abstract Number: 1165
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
-
Abstract Number: 1166
Clinical and Therapeutic Features of 312 Patients with Macrophage Activation Syndrome Enrolled in a Multinational Survey
-
Abstract Number: 1167
Golimumab in 25 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA
-
Abstract Number: 1168
Cost-Effectiveness Analysis of Early Biologic Treatment in Polyarticular Juvenile Idiopathic Arthritis
-
Abstract Number: 1169
Obstetrical Complications in Women with Juvenile Idiopathic Arthritis
-
Abstract Number: 1170
Folate Usage in Methotrexate -Treated Juvenile Idiopathic Arthritis Patients Is Inconsistent and Highly Variable
-
Abstract Number: 1171
Validation of BASDAI and BASFI in Children with Spondyloarthritis
-
Abstract Number: 1172
Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era